QUANTUM GENOMICS : Disclosure of the total number of voting rights and the number of shares of the share capital
Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, has published information on the total number of voting rights and number of shares comprising the share capital on march 9th 2015, in accordance with the provisions of article 223-16.
|Date||Number of shares||Number of voting rights|
|March 9th 2015||6,859,962||Theoretical||7,507,784|
(1) The total number of voting rights is calculated based on the total shares minus shares without voting rights treasury shares. On March 9th 2015, 6,074 shares, representing a total of 6,074 voting rights, were registered under the liquidity contract assigned to the brokerage Aurel BGC.
Chairman & Chief Executive Officer
01 60 13 76 80
CFO - Investor Relations
01 60 13 76 84
ACTUS finance et communication
01 53 67 36 73
ABOUT QUANTUM GENOMICS
Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially high blood pressure and heart failure.
Quantum Genomics is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than 20 years of academic research in the laboratories of the Collège de France, INSERM, CNRS and the University of Paris Descartes.
Quantum Genomics is listed on the Alternext market in Paris (ISIN code FR0011648971, Ticker ALQGC).
Information relative au nombre total de droits de vote et d'actions composant le capital :
Full and original press release in PDF: